Short Term
Mean Reversion
Neutral
Trend
Neutral
Event
Neutral
Halo Model
MQV
Very Strong
GARP
Very Strong
MQV Small
Very Strong
Momentum
Price
Strong
Earnings
Weak
Growth
Earnings
Neutral
Dividends
Very Strong
Quality
Capital Efficiency
Very Strong
Balance Sheet
Very Strong
Telephone
61.8.1300.8133
Address
Fitzroy 425 Smith Street Melbourne, Victoria (VIC) 3065
Description
Dimerix Ltd. engages in the investment of the research and development of biopharmaceutical drugs. It focuses on the development of Dimerix DMX-200 drug candidate in both renal and respiratory indications and the development of Dimerix DMX-700 pre-clinical asset in Chronic Obstructive Pulmonary Disease. The company was founded on May 13, 1975 and is headquartered in Melbourne, Australia.
Market Cap
PE
EV/EBITDA
DIV Yield
Franking
Ex Dividend Date (est.)
52 weeks range
Low 0.06 - 0.67
Trade Value (12mth)
AU$289,020.00
1 week
-16.07%
1 month
-13.76%
YTD
88%
1 year
571.43%
All time high
44.74
EPS 3 yr Growth
61.800%
EBITDA Margin
N/A
Operating Cashflow
-$13m
Free Cash Flow Return
-124.80%
ROIC
-135.30%
Interest Coverage
N/A
Quick Ratio
1.50
Shares on Issue (Fully Dilluted)
406m
HALO Sector
Healthcare
Next Company Report Date
27-Aug-24
Ex Dividend Date (est.)
N/A
Next Dividend Pay Date (est.)
N/A
Reporting Currency
AUD
Short Sell (% of issue)
0.00
Date | Announcements |
---|---|
23 July 24 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
19 July 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
17 July 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
12 July 24 |
Dimerix presentation at Bioshares Biotech Summit
×
Dimerix presentation at Bioshares Biotech Summit |
04 July 24 |
Adolescent Recruitment into ACTION3 Clinical Trial
×
Adolescent Recruitment into ACTION3 Clinical Trial |
03 July 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
26 June 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
21 June 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
13 June 24 |
Dimerix to present at Melbourne Twilight Investor Briefing
×
Dimerix to present at Melbourne Twilight Investor Briefing |
13 June 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
05 June 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
03 June 24 |
Appendices 3Y and Late Lodgement Notice
×
Appendices 3Y and Late Lodgement Notice |
03 June 24 |
Update - Notification of cessation of securities - DXB
×
Update - Notification of cessation of securities - DXB |
31 May 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
27 May 24 |
Dimerix and Taiba enter into License Agreement for DMX-200
×
Dimerix and Taiba enter into License Agreement for DMX-200 |
27 May 24 |
Investor Presentation
×
Investor Presentation |
09 May 24 |
Notification regarding unquoted securities - DXB
×
Notification regarding unquoted securities - DXB |
07 May 24 |
Notification regarding unquoted securities - DXB
×
Notification regarding unquoted securities - DXB |
02 May 24 |
Proposed issue of securities - DXB
×
Proposed issue of securities - DXB |
01 May 24 |
Dimerix Receives PIP Approval from the UK MHRA
×
Dimerix Receives PIP Approval from the UK MHRA |
30 April 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
22 April 24 |
Quarterly Appendix 4C and Activities Report
×
Quarterly Appendix 4C and Activities Report |
22 April 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
12 April 24 |
Notification of cessation of securities - DXB
×
Notification of cessation of securities - DXB |
10 April 24 |
Application for quotation of securities - DXB
×
Application for quotation of securities - DXB |
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Historical data
Forecast data
Load More
Load Less
Percent of Issue
Value ($M)
Prior Change
7 Day Change
1 Month Change
3 Month Change
Access data on short interest, stock performance, and potential short-selling candidates across various markets to make informed decisions and optimize your trading strategies.
Unlock true investor intelligence
Research, trade and manage global markets from one place with HALO Global. It’s trading - the way you want it.
Get the latest insights and hot tips delivered right to your inbox
HALO Technologies Pty Ltd ABN 54 623 830 866 is a Corporate Authorised Representative No 1261916 of Macrovue Pty Ltd ABN 98 600 022 679 AFSL 484264. Macrovue Pty Ltd is a wholly owned subsidiary of HALO Technologies Pty Ltd.